Camizestrant, combined with a CDK4/6 inhibitor, improved progression-free survival by 56% in HR+/HER2– breast cancer patients with ESR1 mutations. Precision medicine, integrating genomics and AI, is ...

The American Society of Clinical Oncology 2025 annual meeting will focus on artificial intelligence’s (AI) role in cancer care, emphasizing biomarker-driven therapeutics and precision medicine ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this episode of Meeting Mic, we bring you pearls and ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of Clinical Oncology conference largely isn’t reflecting that turmoil. In fact ...

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been ...

The coming of age of chimeric antigen receptor (CAR) T-cell therapy, the selection of postinduction therapy on the basis of residual disease activity, and a novel drug delivery system are among the ...

Mariana Chavez MacGregor, MD, MSc, shares her enthusiasm for the 2025 ASCO Annual Meeting, particularly for its relevance to early-stage breast cancer. She highlights key sessions focused on treatment ...

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

All 67 squamous NSCLC patients were EGFR wild type. Among them, 28 patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the two groups of ...